Anaphylaxis Treatment Market

Anaphylaxis is a severe, potentially life-threatening allergic reaction to food, drugs, latex, and Hymenoptera stings. According to a NICE study, anaphylaxis-type reactions occur in ~1 in 1,000 of the general population. During general anesthesia, anaphylaxis occurs in 1 in 10,000–20,000 anesthetics. These patients may be denied general anesthesia in the future unless a safe combination of drugs can be identified. The rise in the patient pool suffering from allergies globally is a major factor driving the anaphylaxis treatment market. 

For instance, in the US and the UK, the incidence of anaphylaxis is 40–500 per million persons, mortality is estimated at 0.63–0.76 per million. In the US, up to 5% of the population suffers from this condition. The growing prevalence of anaphylaxis has increased the demand for its treatment drugs; as per a journal published on NCBI (National Center for Biotechnology Information) in 2017, up to 5% of the U.S. population suffered anaphylaxis condition. Besides, around 1% of total hospitalizations and 0.1% of emergency attendances for anaphylaxis would have fatal outcomes. Drugs are a major cause of fatal anaphylaxis in various countries, such as Australia, New Zealand, the U.K., Brazil, and the U.S. As per a journal published on NCBI, in the year 2018, the lifetime prevalence of anaphylaxis is estimated to be 0.05% – 2% in the U.S., and approx. 3% in Europe. 

Studies on anaphylaxis epidemiology have reported an annual incidence rate of 1.5–50 per 100,000 person-years. According to a study published in the European Journal of Allergy and Clinical Immunology in 2019, the incidence of anaphylaxis in children worldwide varied widely, ranging from 1 to 761 per 100,000 person-years for total anaphylaxis and 1 to 77 per 100,000 person-years for food-related anaphylaxis. In 2016, around 47 out of 10,000 children were diagnosed with anaphylaxis, compared to a rate of 23 per 10,000 in the year 2010. Therefore, anaphylaxis's growing incidence is likely to increase the high uptake of the anaphylaxis treatment market.

COVID-19 is causing a dramatic mismatch of supply and demand that manufacturers are struggling to forecast. On the supply side, manufacturing and supply chain processes in hubs such as China, India, and the United States are being disrupted due to global lockdowns. On the demand side, conflated factors make demand difficult to predict. On the one hand, patients delay seeking treatment, particularly for less convenient administration methods such as infusions, leading to lower patient volume and overall demand. On the other hand, stockpiling and demand for subcutaneous or oral formulations may cause a spike in demand for certain products despite decreasing patient volume. Although all manufacturers are working to mitigate the risk of supply shortages, biosimilar manufacturers that rely on facilities in Europe and Asia may be particularly at risk on the supply side.

Besides, delays in drug approvals and clinical trials are likely to be delayed due to challenges managing protocols, de-prioritization in favor of more immediate acute care needs, and patients’ inability to travel to appointments. Beyond the logistics and prioritization challenges, manufacturers run the risk of trial participants contracting the disease, which leads to poorer outcomes. The pandemic has a positive impact on autoinjectors. The demand for effective home care and remote monitoring has increased autoinjectors' relevance for patients to conveniently and efficiently manage chronic illnesses and allergies without visiting the hospital. This has been especially true in the case of diabetes, Crohn’s disease, and rheumatoid arthritis patients relying on prefilled syringes and autoinjectors to manage their condition at home.

In May 2020, two injectable medications, epinephrine and morphine sulfate were added to the US Food and Drug Administration’s (FDA) guidance on drugs compounded by registered outsourcing facilities. Some smaller compounders are used for patients hospitalized with the novel coronavirus COVID-19. However, on October 15th, 2020, the Food and Drug Administration removed epinephrine from the lists of drugs authorized for temporary compounding during the COVID-19 public health emergency by outsourcing facilities and state-licensed pharmacies or federal facilities not registered as outsourcing facilities. The FDA said epinephrine’s removal is based on increased supplies of FDA-approved epinephrine products used to treat hospitalized COVID-19 patients.

About Us:

DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year, we have secured more than 100 unique customers from established organizations all over the world.

For more information:

Sai Kiran

Sales Manager at DataM Intelligence

Email: [email protected]

Tel: +1 877 441 4866

Website: www.datamintelligence.com